Compare Adaptive Biotechnologies Corp (ADPT) vs Amcor PLC (AMCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Amcor PLC — how do they compare? Adaptive Biotechnologies Corp trades at $24.99 (market cap $4.04B), while Amcor PLC trades at $46.95 (market cap $21.92B). The key difference: Amcor PLC is far larger — about 5.4× Adaptive Biotechnologies Corp's market cap, and Amcor PLC pays a 5.49% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AMCR | |
|---|---|---|
Market Cap | $4.04B | $21.92B |
Sector | Health | Basic Materials |
52-Week High | $25.45 | $50.58 |
52-Week Low | $12.30 | $36.69 |
Enterprise Value | $4.10B | $37.03B |
Dividend Yield | — | 5.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
AMCR trades at $46.85, down 0.55% today, with a bullish technical outlook supported by moving averages and strong earnings beats in the last four quarters. The company reported Q2 2026 EPS of $1.23, exceeding estimates, and maintains a 64% analyst buy rating with a $47.00 consensus target. Recent news highlights expansion in China and strong Q4 results, though net income margin declined to 3.06% in 2025.
The stock presents a balanced opportunity with solid earnings performance and analyst support, but risks include elevated P/E of 38.07, margin pressure, and high debt levels. Upside is capped near-term by technical resistance at $48, while support lies at $46.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →
